This opportunity is no longer accepting applications.
grant RFA-AI-24-065

Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed)

This grant supports early-stage research for developing new drugs to treat specific fungal infections caused by Candida auris, Aspergillus fumigatus, Coccidioides, and Mucorales. It uses a two-phase award system where progression to the second phase depends on achieving certain goals in the first phase.

The purpose of this notice of funding opportunity (NOFO) is to support milestone-driven, early-stage translational research focused on drug discovery and development of novel therapeutics against select fungal pathogens including: Candida species, specifically Candida auris; Aspergillus fumigatu…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Institute of Allergy and Infectious Diseases

Dates

Opportunity Released: September 23, 2024
Open for Submission: September 23, 2024
Submission Deadline: January 28, 2025
Application Window Closes: January 28, 2025

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.